NICE recommends Revlimid (lynadamine) for primary treatment of patients with multiple myeloma

The National Institutes of Health and Care Excellence (NICE) recommends revlimid (lynadamine) from BMS for the initial treatment of patients with multiple myeloma.
INCE recommended Revlimid (Lenadamine) as a maintenance treatment for patients with multiple myeloma who were initially treated after an introphy stem cell transplant (ASCT) in their final evaluation document (FAD).
according to BMS, from today, about 1,150 eligible patients in England will receive Revlimid immediately, with funding from the Cancer Drugs Fund (CDF).
recommendation was supported by two Phase III clinical data, which showed that Revlimid maintenance therapy significantly improved progressive survival (PFS) in patients with primary multiple myeloma compared to placebo.
calGB 100104 study showed that the medium PFS in patients in the Revlimid group was 57.3 months, while the placebo group was 28.9 months.
IFM 2005-02 study showed that the medium PFS in patients in the Revlimid group was 41 months, while the placebo group was 23 months.
, about 1,500 newly diagnosed multiple myeloma patients are treated with ASCT each year, but most eventually relapse.
first remission period is critical for patients with multiple myeloma because it can indicate the overall survival of the disease.
that effective maintenance therapy at this stage of the disease may be "essential" for long-term survival.